Christine Poole Eli Lilly & Co. LLY-N DON'T BUY Mar 21, 2023

Like TJX, their momentum is not unwinding, and shares will push to new all-time highs. It's on a streak now, of 7 straight days, that we haven't seen in 2 years.

Her best performer this month, with revenues growing 40%. Excellent balance sheet, drug pipeline and managers. She just entered this and will buy on dips.

This got expensive, so he reduced his holding at 50x PE, now at 35x. Is still overweight this, because he believes in the GLP franchise. Expects strong revenue growth over 2 years.

Loves healthcare for value and defense. Diabetes and obesity drugs continue to drive sales. Other new drugs boost earnings growth forecast. Sees 25% upside from here. Ranks 10/10 on fundamentals. Yield is 0.72%.

Hold both LLY and NOVO? No. Choose one or the other. LLY sells more diverse drugs and more North American focused.

It's one of the least-tariffed, least-dangerous stocks though the price is high. He sees upside.

Plethora of ideas. Part of the story on cancer. Weight-loss drug is in the lead, and a pill instead of injection is the ultimate goal. Earnings from weight loss will double in 3 years, and then they still have all the other drugs in the pipeline. Yield is 0.70%.

They report Thursday. Their last report laid an egg, but expects this one to be better, so he will hold on.

The more successful of the GLP-1 stocks compared to NVO. Decent entry point. Trades in the 30s on forward PE, so there's a strong expectation of prescription growth; every reason to believe that's going to happen. 

Be cautious on position size; don't be aggressive. Stock was down 10% yesterday because NVO made a deal with CVS to become its prime recommended product for obesity. So NVO is starting to compete more on price.

Data just released says that LLY's weight-loss drug is far better than peer Novo Nordisk. Buy this hand over fist.